Sneha Kapoor
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly
utilized as a primary treatment option for patients with type 2 diabetes
(T2D) due to their efficacy in glycemic control, weight management, and
cardiovascular protection. However, a notable proportion of patients may
require treatment intensification to achieve optimal glycemic targets. This
article reviews the strategies for treatment intensification following the use
of GLP-1 RAs, including the addition of other pharmacologic agents and
lifestyle interventions. A thorough examination of current research reveals
the importance of tailoring treatment plans to address the individual needs
of patients, thereby improving overall outcomes.
